Due diligence frameworks and strategic intelligence for evaluating CGT assets
Why RMAT and BTD status are no longer the de-risking signals investors thought. The Plausible Mechanism Pathway changes how you evaluate gene therapy assets.
A structured framework for evaluating early-stage gene therapy assets — covering CMC readiness, regulatory positioning, IP protection, and team capability.
Portfolio strategy resources coming Q2 2026. Join the expert network to get early access.
Market intelligence resources coming Q3 2026. Join the expert network to get early access.
Our expert consultants are ready to help you evaluate your pipeline and develop winning investment strategies.
Book a Free Discovery Call